Latest Period
Q1 2026
Security Snapshot
Xeris Biopharma Holdings, Inc. - Common Stock (XERS) Institutional Ownership
CUSIP: 98422E103
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
233
Shares (Excl. Options)
105,168,737
Price
$5.80
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- XERS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 105,168,737
- Total 13F value
- $610,298,872
- Portfolio coverage rank
- 0%
- Share change
- +4,554,086
- Value change
- +$15,508,820
- Number of holders
- 233
- Shares outstanding
- 165,974,436
- SEC-reported price per share
- $6.37
- Insider filing price
- $6.37
Latest holder snapshot
5 signals
Issuer context
Who this page is about.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- XERS - Xeris Biopharma Holdings, Inc. - Common Stock is tracked under CUSIP 98422E103.
- 233 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 225 to 233 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $791,465,005 to $610,298,872.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 233 institutions filings for Q1 2026.
Security key
98422E103
Latest holder period
Q1 2026
13F holders
233
13D/G owners
0
CIK / CUSIP context first
Open Q1 2026 holders
XERS full holder history
Xeris Biopharma Holdings, Inc. SEC filings
Xeris Biopharma Holdings, Inc. company facts
Xeris Biopharma Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422E103:
As of 31 Mar 2026, 233 institutional investors reported holding 105,168,737 shares of Xeris Biopharma Holdings, Inc. - Common Stock (XERS). This represents 63% of the company’s total 165,974,436 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.8% | 12,945,785 | +2.4% | 0% | $75,085,553 |
| D. E. Shaw & Co., Inc. | 4.7% | 7,788,811 | +2.8% | 0.04% | $45,175,104 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 6,980,882 | 0% | 0% | $40,489,116 |
| STATE STREET CORP | 2.8% | 4,658,174 | +13% | 0% | $27,017,409 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 4,290,629 | +0.34% | 0% | $24,890,245 |
| Qube Research & Technologies Ltd | 2.5% | 4,114,425 | +18% | 0.03% | $23,863,665 |
| Rosalind Advisors, Inc. | 1.9% | 3,231,700 | +53% | 7.7% | $18,743,860 |
| Nuveen, LLC | 1.8% | 2,916,598 | +3.9% | 0% | $16,916,268 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 2,665,608 | 0% | 0% | $15,460,526 |
| MORGAN STANLEY | 1.6% | 2,572,654 | -5% | 0% | $14,921,395 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 2,265,974 | +164% | 0.01% | $13,142,649 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.3% | 2,171,354 | -5% | 0% | $12,593,854 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 1,924,202 | +11% | 0.01% | $11,160,372 |
| ARMISTICE CAPITAL, LLC | 1.2% | 1,909,838 | 0.37% | $11,077,060 | |
| Legal & General Group Plc | 1.1% | 1,908,289 | +37% | 0% | $11,068,077 |
| Parkman Healthcare Partners LLC | 1% | 1,721,264 | +1.8% | 1% | $9,983,331 |
| UBS Group AG | 0.99% | 1,646,378 | +174% | 0% | $9,548,993 |
| GOLDMAN SACHS GROUP INC | 0.97% | 1,613,650 | +2.9% | 0% | $9,359,170 |
| NORTHERN TRUST CORP | 0.87% | 1,444,617 | +4.2% | 0% | $8,378,778 |
| AQR CAPITAL MANAGEMENT LLC | 0.84% | 1,394,376 | +46% | 0% | $8,087,382 |
| Voss Capital, LP | 0.84% | 1,386,927 | +273% | 0.46% | $8,044,177 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.82% | 1,359,657 | -3.1% | 0% | $7,886,011 |
| CenterBook Partners LP | 0.75% | 1,248,621 | -10% | 0.39% | $7,242,002 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.75% | 1,240,692 | +2.2% | 0.15% | $7,196,014 |
| ALGERT GLOBAL LLC | 0.7% | 1,156,958 | +61% | 0.1% | $6,710,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 105,168,737 | $610,298,872 | +$15,508,820 | $5.80 | 233 |
| 2025 Q4 | 100,824,477 | $791,465,005 | +$25,604,813 | $7.85 | 225 |
| 2025 Q3 | 96,875,375 | $788,604,319 | +$58,407,551 | $8.14 | 228 |
| 2025 Q2 | 90,495,534 | $422,617,978 | +$16,622,096 | $4.67 | 200 |
| 2025 Q1 | 86,799,982 | $476,523,606 | +$123,713,876 | $5.49 | 199 |
| 2024 Q4 | 65,548,446 | $222,208,577 | +$5,693,687 | $3.39 | 161 |
| 2024 Q3 | 63,918,467 | $182,169,401 | +$11,712,690 | $2.85 | 143 |
| 2024 Q2 | 60,623,914 | $136,403,872 | +$57,516 | $2.25 | 132 |
| 2024 Q1 | 60,495,199 | $133,691,334 | +$1,259,202 | $2.21 | 140 |
| 2023 Q4 | 59,921,867 | $140,817,138 | +$3,980,290 | $2.35 | 118 |
| 2023 Q3 | 55,319,172 | $102,889,496 | -$2,383,422 | $1.86 | 109 |
| 2023 Q2 | 55,920,487 | $146,506,955 | +$17,809,976 | $2.62 | 101 |
| 2023 Q1 | 49,463,144 | $80,622,599 | -$5,927,964 | $1.63 | 89 |
| 2022 Q4 | 53,916,182 | $71,703,555 | -$5,395,029 | $1.33 | 93 |
| 2022 Q3 | 57,306,752 | $89,403,802 | -$3,332,109 | $1.56 | 97 |
| 2022 Q2 | 59,291,260 | $91,305,115 | +$12,225,836 | $1.54 | 95 |
| 2022 Q1 | 50,404,861 | $129,034,768 | +$23,839,809 | $2.56 | 97 |
| 2021 Q4 | 40,971,724 | $120,062,000 | +$117,961,261 | $2.93 | 85 |
| 2021 Q3 | 704,170 | $1,725,000 | +$1,725,000 | $2.45 | 1 |